Hologic (HOLX) – StreetInsider.com Reports
-
Citi Upgrades Sotera Health (SHC) to Buy
-
Citi Upgrades Hologic (HOLX) to Buy
-
Citi Downgrades Bio-Rad Labs (BIO) to Neutral
-
Hologic (HOLX) Reports New Study Showing Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
-
FDA warns of potential risk from Hologic's devices implanted in soft tissue
-
Hologic (HOLX) PT Raised to $84 at Morgan Stanley
-
Hologic (HOLX) PT Raised to $79 at UBS
-
Hologic (HOLX) PT Raised to $90 at Needham & Company
-
Hologic (HOLX) Genius Digital Diagnostics System with the Genius Cervical AI algorithm gains FDA clearance
-
Hologic (HOLX) Tops Q1 EPS by 3c ; Offers Guidance
-
Hologic (HOLX) Announces Resignation of Namal Nawana from Board
-
Hologic (HOLX) Reports Prelim Q1 Revenue of $1.01B
-
William Blair's top large cap picks for 2024
-
Hologic (HOLX) PT Lowered to $78 at UBS
-
Hologic (HOLX) PT Lowered to $82 at Morgan Stanley
-
Hologic (HOLX) PT Lowered to $85 at JPMorgan
-
Hologic (HOLX) PT Lowered to $72 at RBC Capital
-
Hologic (HOLX) PT Lowered to $73 at Evercore ISI
-
Hologic stock gains 2% on better than expected Q4 results
-
After-hours movers: The Trade Desk, Unity Software plunge on guidance issues
-
Hologic (HOLX) Tops Q4 EPS by 5c; offers guidance
-
Hologic (HOLX) option IV flat into quarter results and outlook
-
Hologic (HOLX) PT Lowered to $83 at Needham & Company
-
Hologic (HOLX) PT Lowered to $75 at BofA Securities
-
Hologic (HOLX) PT Lowered to $85 at Raymond James
-
Hologic (HOLX) PT Lowered to $85 at Mizuho Securities
-
Hologic (HOLX) Announces Innovative Collaboration with AAGL and Inovus Medical to Optimize OB-GYN Training for Minimally Invasive Surgeries
-
Hologic (HOLX) Appoints Nanaz Mohtashami to its Board
-
Hologic (HOLX) and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities
-
Hologic (HOLX) PT Lowered to $91 at UBS
-
Hologic (HOLX) PT Lowered to $95 at JPMorgan
-
Hologic (HOLX) PT Lowered to $95 at Raymond James
-
Hologic (HOLX) PT Lowered to $85 at RBC Capital
-
Hologic (HOLX) PT Lowered to $86 at BofA Securities
-
Hologic (HOLX) PT Lowered to $80 at Evercore ISI
-
Hologic (HOLX) Tops Q3 EPS by 4c; Offers Guidance
-
Hologic (HOLX) shares undervalued - Needham & Company
-
Needham & Company Upgrades Hologic (HOLX) to Buy as COVID-related headwind will soon end
-
Hologic (HOLX) Granted FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
-
Hologic (HOLX) PT Raised to $86 at Morgan Stanley
-
Hologic (HOLX) PT Raised to $93 at UBS
-
Hologic (HOLX) PT Raised to $105 at JPMorgan
-
Hologic (HOLX) PT Raised to $95 at Mizuho Securities
-
Hologic (HOLX) PT Raised to $100 at Raymond James
-
Hologic (HOLX) PT Raised to $85 at Wells Fargo
-
Hologic (HOLX) PT Raised to $90 at Evercore ISI
-
Hologic (HOLX) PT Raised to $90 at Citi
-
Hologic (HOLX) Tops Q2 EPS by 21c; raises guidance
-
Hologic (HOLX) Announces Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent
-
Hologic (HOLX) Announces NovaSure V5 Global Endometrial Ablation Device Approved for Use in Canada and Europe
Back to HOLX Stock Lookup